Table 1.

Main characteristics of the studies included in the meta-analysis.

Studies	Study design	Type of infection	Drug Regimen		Treatment duration (day)	Time to TOC (day)	Telavancin vs. comparator group (No. of patients)			Quality score
			Telavancin	Comparator			mITT	CE	ME
Stryjewski et al., 2014	MN,DB,Phase II RCT	SAB	10 mg/kg q 24 h	vancomycin 1 g q 12 h, or nafcillin or oxacillin or cloxacillin 2 g q 6 h	12–15	84	29 vs. 29	8 vs. 9	8 vs. 9	3
Stryjewski et al., 2006	MC,DB,Phase II RCT	cSSSI	10 mg/kg q 24 h	vancomycin 1 g q 12 h, or nafcillin or oxacillin 2g or cloxacillin at 0.5 to 1 g q 6 h	4–14	7–14	100 vs. 95	77 vs. 77	64 vs. 57	3
Stryjewski et al., 2005	MC,DB,Phase II RCT	cSSSI	7.5mg/kg q 24 h	vancomycin 1 g q 12 h, or nafcillin or oxacillin 2g or cloxacillin at 0.5 to 1 g q 6 h	4–14	7–14	84 vs. 83	72 vs. 69	56 vs. 56	3
Rubinstein et al., 2011a,b	2 MC,DB,Phase III RCTs	HAP	10 mg/kg q 24 h	vancomycin 1 g q 12 h	7–14	7–14	749 vs. 754	312 vs. 342	243 vs. 237	2
Stryjewski et al., 2008	2 MC,DB,Phase III RCTs	cSSSI	10 mg/kg q 24 h	vancomycin 1 g q 12 h	7–14	7–14	928 vs. 939	745 vs. 744	527 vs. 536	2

Abbreviations: MN, multinational; MC, multicenter; DB, double-blinded; vs., versus; RCT, randomized controlled trial; TOC, test of cure; mITT, modified Intention-to-Treat; CE, clinically evaluable; ME, microbiologically evaluable; SAB, uncomplicated Staphylococcus aureus bacteremia; cSSSI, complicated skin and skin structure infection; HAP, hospital-acquired pneumonia.